The magnitude of the COVID-19 pandemic globally is generating considerable interest in options to prevent infection and minimize the impact if infection occurs. Pre-exposure prophylaxis and post-exposure treatment with a group of drugs called antivirals, sometimes in combination with an antibiotic, have been the subject of public debate and, at times, significant media reporting. Join us on Friday, May 29, 2020 for the evidence on two specific antiviral treatments that have been widely discussed — hydroxychloroquine (with or without the antibiotic azithromycin) and remdesivir. You’ll also learn about the clinical trials underway on the use of antivirals in preventing and treating COVID-19.
- Dr. Gordon H. Guyatt
- Dr. Tarry Ahuja
- Heather Logan
To participate, please register (there is no cost). After registering, you will receive a confirmation email with information about how to join the webinar.